180 related articles for article (PubMed ID: 22918720)
1. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Seiwert T; Sarantopoulos J; Kallender H; McCallum S; Keer HN; Blumenschein G
Invest New Drugs; 2013 Apr; 31(2):417-24. PubMed ID: 22918720
[TBL] [Abstract][Full Text] [Related]
2. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
Shah MA; Wainberg ZA; Catenacci DV; Hochster HS; Ford J; Kunz P; Lee FC; Kallender H; Cecchi F; Rabe DC; Keer H; Martin AM; Liu Y; Gagnon R; Bonate P; Liu L; Gilmer T; Bottaro DP
PLoS One; 2013; 8(3):e54014. PubMed ID: 23516391
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.
Abdul Razak AR; Soulières D; Laurie SA; Hotte SJ; Singh S; Winquist E; Chia S; Le Tourneau C; Nguyen-Tan PF; Chen EX; Chan KK; Wang T; Giri N; Mormont C; Quinn S; Siu LL
Ann Oncol; 2013 Mar; 24(3):761-9. PubMed ID: 23108949
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
Fujii M; Tomita K; Nishijima W; Tsukuda M; Hasegawa Y; Ishitoya J; Yamane H; Homma A; Tomita T
Jpn J Clin Oncol; 2010 Mar; 40(3):214-21. PubMed ID: 19934112
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
8. A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Yau TCC; Lencioni R; Sukeepaisarnjaroen W; Chao Y; Yen CJ; Lausoontornsiri W; Chen PJ; Sanpajit T; Camp A; Cox DS; Gagnon RC; Liu Y; Raffensperger KE; Kulkarni DA; Kallender H; Ottesen LH; Poon RTP; Bottaro DP
Clin Cancer Res; 2017 May; 23(10):2405-2413. PubMed ID: 27821605
[No Abstract] [Full Text] [Related]
9. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
10. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Specenier P; Rasschaert M; Vroman P; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Am J Clin Oncol; 2011 Oct; 34(5):472-7. PubMed ID: 20938321
[TBL] [Abstract][Full Text] [Related]
11. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Geiger JL; Bauman JE; Gibson MK; Gooding WE; Varadarajan P; Kotsakis A; Martin D; Gutkind JS; Hedberg ML; Grandis JR; Argiris A
Head Neck; 2016 Dec; 38(12):1759-1764. PubMed ID: 27232378
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.
Hanrahan EO; Kies MS; Glisson BS; Khuri FR; Feng L; Tran HT; Ginsberg LE; Truong MT; Hong WK; Kim ES
Am J Clin Oncol; 2009 Jun; 32(3):274-9. PubMed ID: 19433965
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
[TBL] [Abstract][Full Text] [Related]
17. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
Swiecicki PL; Zhao L; Belile E; Sacco AG; Chepeha DB; Dobrosotskaya I; Spector M; Shuman A; Malloy K; Moyer J; McKean E; McLean S; Wolf GT; Eisbruch A; Prince M; Bradford C; Carey T; Worden FP
Invest New Drugs; 2015 Dec; 33(6):1248-56. PubMed ID: 26453566
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Malhotra B; Moon J; Kucuk O; Clark JI; Urba SG; Wolf GT; Worden FP
Head Neck; 2014 Dec; 36(12):1712-7. PubMed ID: 24166832
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
